Efficacy and tolerability of agomelatine in the treatment of depression

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 603-612

  Plesničar, Blanka Kores ^a  

^a UNIVERSITY PSYCHIATRIC HOSPITAL   (Slovenia)

Author keywords

Agomelatine; Circadian rhythms; Depression

Indexed keywords

AGOMELATINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

CIRCADIAN RHYTHM; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; INSOMNIA; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; MULTICENTER STUDY (TOPIC); NAUSEA; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SINGLE DRUG DOSE; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84899839151     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S42789     Document Type: Review

References (63)

1. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B; CDBE2010 study group. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155-162.
2. Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psychiatr Soc. 2009;18(1):23-33.
3. Hickie I. Is depression overdiagnosed? No. BMJ. 2007;335:329.
4. American Psychiatric Association (APA). Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. Arlington, VA: APA; 2010.
5. National Institute for Health and Care Excellence (NICE) [webpage on the Internet]. Depression: the treatment and management of depression in adults (update). NICE clinical guideline 90. NICE; 2009 [updated February 6, 2014]. Available at: http://www.nice.org.uk/CG90. Accessed February 18, 2014.
6. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder. Potential for clinical effectiveness. CNS Drugs. 2010;24(6): 479-499.
7. Kennedy SH, Eisfeld BS, Meyer JH, Bagby RM. Antidepressants in clinical practice: limitations of assessment methods and drug response. Hum Psychopharmacol. 2001;16(1):105-114.
8. Mann JJ. The medical management of depression. N Engl J Med. 2005;353(17):1819-1834.
9. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011;378(9791): 621-631.
10. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927-947.
11. Lader M. Limitation of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target. Eur Neuropsychopharmacol. 2007;17:743-755.
12. Etain B, Milhiet V, Bellvier F, Leboyer M. Genetics of circadian rhythms and mood spectrum disorders. Eur Neuropsychopharmacol. 2011;21:676-682.
13. Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet. 2008;9:764-775.
14. Racagni G, Riva MA, Popoli M. The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol. 2007;22 Suppl 2:S9-S14.
15. Kennaway DJ. Clock genes at the heart of depression. J Psychopharmacol. 2010;24 Suppl 8:5-14.
16. Scott J. Clinical parameters of circadian rhythms in affective disorders. Eur Neuropsychopharmacol. 2011;21:671-675.
17. De Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Munǒz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9(8):628-642.
18. McClung CA. Circadian rhythms and mood regulation: insights from pre-clinical models. Eur Neuropsychopharmacol. 2011;21 Suppl 4:S683-S693.
19. Courtet P, Olie E. Circadian dimension and severity of depression. Eur Neuropsychopharmacol. 2012;22 Suppl 3:S467-S481.
20. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004;65 Suppl 16:27-32.
21. Almeida OP, Pfaff JJ. Sleep complaints among older general practice patients: association with depression. Br J Gen Pract. 2005;55(520): 864-866.
22. Shaffery J, Hoffmann R, Armitage R. The neurobiology of depression: perspectives from animal and human sleep studies. Neuroscientist. 2003;9(1):82-98.
23. Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry. 2005;66(10):1254-1269.
24. Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci. 1995;15(5 Pt 1):3526-3538.
25. Hickie I, Davenport T. A behavioural approach based on reconstructing the sleep-wake cycle. Cogn Behav Pract. 1999;6:442-450.
26. Swartz HA, Maihoefer CC, Frank E, et al. Implementing interpersonal and social rhythm therapy for mood disorders across a continuum of care. Psychiatric Serv. 2011;62(11):1377-1380.
27. Duffy JF, Czeisler CA. Effects of light on human circadian physiology. Sleep Med Clin. 2009;4(2):165-177.
28. Wirz-Justice A. Diurnal variations of depressive symptoms. Dialogues Clin Neurosci. 2008;10(3):337-343.
29. Wu JC, Kelsoe JR, Schachat C, et al. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry. 2009;66(3):298-301.
30. Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci. 2000;25(1):48-52.
31. Demyttenaere K. Agomelatine: a narrative review. Eur Neuropsychopharmacol. 2011;21 Suppl 4:703-709.
32. Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol. 2007;10(5):575-578.
33. Sansone RA, Sansone LA. Agomelatine, a novel antidepressant. Inn Clin Neuroscience. 2011;8(11):10-14.
34. Pompili M, Serafini G, Innamorati M, et al. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J Biol Psychiatry. 2013;14(6):412-431.
35. Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult to-treat-depression. Biol Psychiatry. 2003;53(8):707-742.
36. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanism. Neuropsychopharmacology. 2008;33(1): 88-109.
37. Bachis A, Mallei A, Cruz MI, Wellstein A, Mocchetti I. Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neuropharmacology. 2008;55(7):1114-1120.
38. Molteni R, Calabrese F, Pisoni S, et al. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry. 2010;11(2):148-153.
39. Soumier A, Banasr M, Lortet S, et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacol. 2009;34(11):2390-2403.
40. European Medicines Agency (EMA) [webpage on the Internet]. Valdoxan: Summary of Product Characteristic. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product-Information/human/000915/WC500046227.pdf. Accessed April 16, 2014.
41. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17(5):239-247.
42. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16(2):93-100.
43. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonist properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10(5):661-673.
44. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010;71(5): 616-626.
45. Lemoine P, Guilleminault CAE, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68(11):1723-1732.
46. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Psychopharmacol Bull. 2010;43(3):15-25.
47. Kasper S, Hajak G, Wulff C, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71(2):109-120.
48. Laux G; VIVALDI study group. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry. 2012;45(7):284-291.
49. Kasper S, Corruble E, Hale A, Lemoine P, Montgomery SA, Quera-Salva MA. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Int Clin Psychopharmacol. 2013;28(1):12-19.
50. Demyttenaere K, Corruble E, Hale A, Quera-Salva MA, Picarel-Blanchot F, Kasper S. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr. 2013;18(3): 163-170.
51. Goodwin GM, Emsley R, Rembry S, Rouillon F; Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo controlled trial. J Clin Psychiatry. 2009;70(8):1228-1137.
52. Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007;10(5):691-696.
53. Martinotti G, Sepede G, Gambi F, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder. J Clin Psychpoharmacol. 2012;32(4):487-491.
54. Di Giannantonio M, Di Iorio G, Guglielmo R, et al. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Reg Hom Agents. 2011;25(1):109-114.
55. Thome J, Poley P. Agomelatine: an agent against anhedonia and abulia? J Neural Transm. Epub December 6, 2013.
56. Stone M, Laughten T, Jones L, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.
57. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 2005;62(2):165-172.
58. Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ. 2005;330(7488):389-393.
59. Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry. 2013;203(3):179-187.
60. Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013;12:CD008851.
61. Monteyo A, Majadas S, Rizvi SJ, Kennedy SH. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol. 2011;26(8):537-542.
62. Voican CS, Corruble L, Naveau S, Perlemuter G. Antidepresasant-induced liver injury: a review for clinicians. Am J Psychiatry. Epub December 20, 2013.
63. Gahr M, Freudenmann RW, Connemann BJ, Hiemke C, Schönfeldt-Lecuona C. Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry. 2013;46(6):214-220.